Physician profile
Aaron Lesser
NPI 1831798677
$2,865.43
in general payments reported to CMS, 2019-2025
32 companies · $371 in 2025
The $371 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $344 · 2022: $560 · 2023: $854 · 2024: $737 · 2025: $371.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,962.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,962.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,073.92 | 2021-2025 | |
| Lilly USA, LLC | $356.72 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Otsuka America Pharmaceutical, INC. | $111.64 | 2022-2025 | Rexulti |
| Biohaven Pharmaceutical Holding Company LTD. | $105.84 | 2022 | |
| Novo Nordisk INC | $92.09 | 2023-2025 | Wegovy |
| Pfizer INC. | $91.57 | 2023-2024 | |
| Amgen INC. | $89.40 | 2021-2024 | Otezla, Repatha |
| Neurocrine Biosciences, INC. | $87.33 | 2022-2023 | Ingrezza |
| Novartis Pharmaceuticals Corporation | $67.34 | 2022-2023 | |
| Organon LLC | $66.09 | 2021-2024 | |
| Biohaven Pharmaceuticals, INC. | $63.91 | 2021 | |
| Lundbeck LLC | $57.40 | 2022-2024 | Rexulti |
| Astellas Pharma US INC | $56.92 | 2023-2024 | Veozah |
| Idorsia Pharmaceuticals US INC | $56.85 | 2022-2024 | Quviviq |
| Astrazeneca Pharmaceuticals LP | $56.55 | 2021-2023 | Farxiga |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acella Pharmaceuticals, LLC | $52.39 | 2024-2025 | NP Thyroid 60 |
| Bayer Healthcare Pharmaceuticals INC. | $41.54 | 2024-2025 | |
| Teva Pharmaceuticals USA, INC. | $40.08 | 2023-2024 | Ajovy, Austedo Xr |
| Exact Sciences Corporation | $38.10 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $36.30 | 2024 | Caplyta |
| Alnylam Pharmaceuticals INC. | $26.02 | 2024 | Givlaari |
| Vertex Pharmaceuticals Incorporated | $24.48 | 2025 | |
| Amarin Pharma, INC. | $20.10 | 2021 | |
| Phadia US INC. | $19.31 | 2023 | Immunocap |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.07 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $18.93 | 2021 | |
| Corcept Therapeutics | $18.28 | 2021 | |
| Janssen Pharmaceuticals, INC | $18.23 | 2024 | Spravato |
| Phathom Pharmaceuticals, INC. | $17.49 | 2024 | Voquezna |
| Exeltis, USA INC. | $16.99 | 2025 | Slynd |
| Smith+Nephew, INC. | $12.60 | 2022 | |
| Alkermes, INC. | $11.95 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aaron Lesser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.